| 摘要 |
<p>A coformulation of an active (preferably pharmaceutically active, for instance a COX-2 enzyme inhibitor) substance and an oligomeric or polymeric excipient, containing at least 10 % of the active, between 80 and 100 % of which is amorphous. The amorphous phase is stable, with respect to the crystalline phase(s), for at least theree months after its preparation when stored at between O and 10 °C. The invention also provides processes, preferably involving SEDSTM particle formation, for preparing such a coformulation.</p> |
